Skip to main content
SOLIGENIX, INC. logo

SOLIGENIX, INC. — Investor Relations & Filings

Ticker · SNGX ISIN · US8342233074 LEI · 549300MN2EF9LQHLT817 US Manufacturing
Filings indexed 1,023 across all filing types
Latest filing 2026-05-08 Prospectus
Country US United States of America
Listing US SNGX

About SOLIGENIX, INC.

https://www.soligenix.com/

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company operates through two main segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics pipeline develops treatments for orphan diseases. The Public Health Solutions pipeline, funded by government grants and contracts, focuses on developing vaccines and therapeutics for infectious diseases and biodefense applications, including a program to prevent ricin poisoning.

Recent filings

Filing Released Lang Actions
424B3
Prospectus
2026-05-08 English
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
Prospectus
2026-05-08 English
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
Prospectus
2026-05-08 English
424B3
Prospectus
2026-05-08 English
10-Q
Interim / Quarterly Report
2026-05-08 English
8-K - SOLIGENIX, INC. (0000812796) (Filer)
Regulatory Filings
2026-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.